[CAS NO. 934369-14-9] TY-52156
PRODUCTS SPECIFICATIONS [934369-14-9]
DESCRIPTION [934369-14-9]
Overview
| MDL | MFCD28396419 |
|---|---|
| Molecular Weight | 364.27 |
| Molecular Formula | C18H19Cl2N3O |
| SMILES | ClC1=CC=C(/N=C(NNC2=CC=C(Cl)C=C2)/C(C(C)(C)C)=O)C=C1 |
5 Publications Citing Use of MCE
Summary
TY-52156 is a potent and selective S1P 3 receptor antagonist with a K i value of 110 nM [1] .
IC50 & Target
Ki: 110 nM (S1P 3 ) [1]
In Vitro
TY-52156 inhibits the S1P
3
receptor-dependent increase in [Ca
2+
]
i
[1]
.
TY-52156 shows submicromolar potency and a high degree of selectivity for S1P
3
receptor
[1]
.
TY-52156 (10 μM; 10 min) inhibits S1P-induced p44/p42 MAPK phosphorylation
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | Chinese hamster ovary K1 cells |
| Concentration: | 10 μM |
| Incubation Time: | 10 min |
| Result: | Inhibited S1P-induced p44/p42 MAPK phosphorylation. |
In Vivo
TY-52156 (10 mg/kg, 30 mg/kg; p.o.) suppresses S1P
3
receptor-induced bradycardia after oral administration in vivo
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male SD rats (290–340 g) [1] |
| Dosage: | 10 mg/kg, 30 mg/kg |
| Administration: | Oral administration |
| Result: | Inhibited S1P 3 receptor-induced bradycardia after oral administration in vivo. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 274.52 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.7452 mL | 13.7261 mL | 27.4522 mL |
| 5 mM | 0.5490 mL | 2.7452 mL | 5.4904 mL |
| 10 mM | 0.2745 mL | 1.3726 mL | 2.7452 mL |
-
1.
Synonyms